Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

40.77
+0.03500.09%
Volume:139.62K
Turnover:5.68M
Market Cap:1.05B
PE:- -
High:40.94
Open:40.57
Low:40.35
Close:40.73
52wk High:43.52
52wk Low:28.77
Shares:25.65M
Float Shares:25.65M
Volume Ratio:2.26
T/O Rate:0.54%
Dividend:0.29
Dividend Rate:0.71%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

European Shares Gain as Genmab Jumps, Bond Yields Retreat

Reuters
·
1 hour ago

LIVE Markets-a Health Boost for the STOXX

Reuters
·
2 hours ago

Genmab at 3-Year High After Blood Cancer Drug Combination Study Results

Reuters
·
3 hours ago

Tech Coast Angels Reports Profitable Atraverse Medical Exit After Johnson & Johnson Acquisition, Citing 70%+ IRR

Reuters
·
10 hours ago

L'Oreal Explores Unloading Chemical-Related Liabilities, WSJ Reports

Reuters
·
12 hours ago

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
13 hours ago

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
13 hours ago

Bristol-Myers Squibb Co: Prelim Total Acquired Iprd and Licensing Income $1,536 Mln for Three Months Ended September 30, 2026

THOMSON REUTERS
·
14 hours ago

AbbVie Cuts Q3 Adjusted Diluted EPS Outlook to $3.73-$3.77 After $216 Million Acquired Ipr&d, Milestones Expense

Reuters
·
14 hours ago

Abbvie - Full-Year 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $13.76-$13.96 - SEC Filing

THOMSON REUTERS
·
14 hours ago

Abbvie - Q3 2026 Gaap and Adj Earnings Include $216 Mln Bought Ipr&D and Milestones Expense - SEC Filing

THOMSON REUTERS
·
14 hours ago

Abbvie Inc. Fy2026 Shr View $14.02

THOMSON REUTERS
·
14 hours ago

Abbvie - Q3 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $3.73-$3.77 - SEC Filing

THOMSON REUTERS
·
14 hours ago

Genmab, AbbVie Say New Drug Combo Helps Lymphoma Patients Stay Cancer-Free Longer

MT Newswires Live
·
14 hours ago

Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL

TIPRANKS
·
14 hours ago

AbbVie Blood Cancer Drug Combo Cuts Risk of Progression or Death in Late-Stage Study

Reuters
·
14 hours ago

Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study

TIPRANKS
·
15 hours ago

Genmab Says Phase 3 Epcore DLBCL-2 Trial Shows Epcoritamab Plus R-CHOP Cuts Progression or Death Risk 51% in Newly Diagnosed DLBCL

Reuters
·
15 hours ago

Genmab - Phase 3 Trial Shows 51% Reduction in Risk of Progression or Death in Dlbcl

THOMSON REUTERS
·
15 hours ago

Genmab: Safety Profile of Epcoritamab When Administered in Combination with Standard of Care R-Chop was Generally Well Tolerated

THOMSON REUTERS
·
15 hours ago